Class summary at a glance.

Every drug in the Aromatic Amino Acid class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $44.9Mcombined across class
Total Rx claims: 14K5K unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Levodopa

Brand: Inbrija · 14K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2018-12-22

Brand-only (no generics) 190 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $44.9M

Class share

100%

of class CY24 spend

View profile →

Carbidopa and Levodopa

Brand: CREXONT · — Part D claims (CY24) · First FDA approval: 1993-09-01

Brand-only (no generics) 9 plans require PA

Low NADAC$0.074

→

Avg plan cost$0.561

Part D spend — 8× spread, current vs floor

Class share

of class CY24 spend

View profile →

Carbidopa, Levodopa and Entacapone

— Part D claims (CY24) · First FDA approval: 2021-08-05

3 generic mfrs 0 plans require PA

Low NADAC$0.636

→

Avg plan cost$0.699

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.